This profile was last updated on //
Is this you? Claim your profile.
DS Laboratories Inc
1601 Green Road
DS Laboratories is committed to being a consummate corporate citizen. We strongly believe that as a business we have a responsibility to society, the environment, and to improving the lives of those around us.
We strongly believe that some of the most
Find other employees at this company (52)
(182 Total References)
DS Healthcare Group Inc (NASDAQ:DSKX) Shareholder Alert: Lawsuit Alleges False and Misleading Statements | Apr 27, 2016 - SBWire
Additionally, DS Healthcare Group Inc disclosed that the Audit Committee and independent counsel had started an investigation into the Company President, Daniel Khesin's, involvement in the allegedly fraudulent revenue recognition and equity transaction errors; and that Mr. Khesin's employment as President of DS Healthcare Group Inc has been terminated for cause based on the current results of the investigation.
Robbins Arroyo LLP: DS Healthcare Group, Inc. (DSKX) Misled Shareholders According to a Recently Filed Class Action | Business Wire
DS also disclosed that its Board of Directors terminated Daniel Khesin as President for cause and removed him as its Chairman of the Board for cause because they believed he violated his fiduciary duty to the company and its subsidiaries and may have violated federal law.
Then, on April 3, 2016, DS disclosed that Khesin engaged in inappropriate conduct, additional violations of the federal securities laws, and intimidation and defamation against Board members, management, and outside professionals.
On this news, DS stock fell $0.18 per share, or over 21%, to close at $0.67 per share before NASDAQ halted trading on April 4, 2016.
On April 5, 2016, DS filed a verified emergency motion for temporary restraining order and preliminary injunction to protect the company from Khesin's alleged continued unlawful misconduct.
DS Healthcare also revealed ...
DS Healthcare also revealed that the Audit Committee and independent counsel had started an investigation into the involvement of the company's President, Daniel Khesin, in the allegedly fraudulent revenue recognition and equity transaction errors; and that Mr. Khesin's employment as President of DS Healthcare has been terminated for cause based on the current results of the investigation.
Barch-Niles succeeds Daniel ...
Barch-Niles succeeds Daniel Khesin, DS Healthcare's founding CEO.
Khesin will continue to serve as Chairman and will lead product innovation.